Gedatolisib, Faslodex, and Ibrance combination significantly improved progression-free survival in advanced breast cancer patients, reducing disease progression risk by 76%. The triplet regimen ...
Gedatolisib plus fulvestrant and palbociclib (the “gedatolisib-triplet”) reduced the risk of disease progression or death by 50% vs. alpelisib plus fulvestrant (HR=0.50; 95% CI: 0.37–0.68; p<0.0001).
Breast cancer treatment has been a showcase of increasing precision—from surgery and chemotherapy, to endocrine therapies and targeted treatments. Breast cancer subtypes can be defined by expression ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results